Cutaneous manifestations of thrombophilia;Manifestações cutâneas das trombofilias

Anais Brasileiros de Dermatologia

Volumn 83, Issue 6, 2008, Pages 491-506

  Criado, Paulo Ricardo ^a,b   Valente, Neusa Y S ^a   Rivitti, Evandro A ^a   Martins, Jose Eduardo Costa ^a   Vasconcellos, Cidia ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Departamento de Dermatologia da Faculdade de Medicina da Universidade de São Paulo ^*  (Brazil)

Author keywords

Factor V; Leg ulcer; Purpura; Skin diseases, vascular; Thrombophilia; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; PROTHROMBIN;

ANTIPHOSPHOLIPID SYNDROME; ANTITHROMBIN DEFICIENCY; CLINICAL FEATURE; ENTERITIS; GENE MUTATION; GENETIC DISORDER; HUMAN; HYPERCOAGULABILITY; HYPERHOMOCYSTEINEMIA; LABORATORY TEST; LEG ULCER; MALIGNANT NEOPLASTIC DISEASE; MEDICAL SPECIALIST; MYELOPROLIFERATIVE DISORDER; NEPHROTIC SYNDROME; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; PURPURA; REVIEW; SKIN DISEASE; SKIN NECROSIS; THROMBOPHILIA; VASCULAR DISEASE;

EID: 63149089819     PISSN: 03650596     EISSN: 18064841     Source Type: Journal    
DOI: 10.1590/S0365-05962008000600002     Document Type: Review

References (71)

1. Garcia AA, Franco RF. Trombofilias adquiridas. Medicina, Ribeirão Preto. 2001;34:258-68.
2. Johnson CM, Mureebe L, Silver D. Hypercoagulable states: a review. Vasc Endovasc Surg. 2005;39:123-33.
3. Franco RF. Trombofilias hereditárias. Medicina, Ribeirão Preto. 2001;34:248-57.
4. Kuhle S, Male C, Mitchell L. Developmental hemostasis: pro-and anticoagulant systems during childhood. Semin Thromb Hemost. 2003;29:329-38.
5. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, et al. A population- based perspective of the hospital incidence and case- fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med. 1991;151:933-8.
6. Nordstrom M, Lindblad B, Bergqvist D, Kjellström T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med. 1992;232:155-60.
7. Jordan FL, Nandorff A. The familial tendency in thromboembolic disease. Acta Med Scand. 1956; 156: 267-75.
8. De Stefano V, Rossi E, Paciaroni K, Leone G. Screening for inherited thrombophilia: indications and therapeutic implications. Haematologica. 2002; 87: 1095-108.
9. De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood. 1996;87:3531-44.
10. Franco RF, Trip MD, ten Cate H, van den Ende A, Prins MH, Kastelein JJ, et al. The 20210 G->A mutation in the 3'-untranslated region of the prothrombin gene and the risk for arterial thrombotic disease. Br J Haematol. 1999;104:50-4.
11. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698-703.
12. Kearon C, Crowther M, Hirsh J. Management of patients with hereditary hypercoagulable disorders. Annu Rev Med. 2000;51:169-85.
13. Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, et al. Inherited thrombophilia: Part 1.Thromb Haemost. 1996;76:651-62.
14. Sagar S, Nairn D, Stamatakis JD, Maffei FH, Higgins AF, Thomas DP, et al. Efficacy of low-dose heparin in prevention of extensive deep-vein thrombosis in patients undergoing total-hip replacement. Lancet. 1976;1:1151-4.
15. Clouse LH, Comp PC. The regulation of hemostasis: the protein C system. N Engl J Med. 1986;314:1298-304.
16. van Wijnen M, Stam JG, van't Veer C, Meijers JC, Reitsma PH, Bertina RM, et al. The interaction of protein S with the phospholipid surface is essential for the activated protein C-independent activity of protein S. Thromb Haemost. 1996;76:397-403.
17. Gómez E, Ledford MR, Pegelow CH, Reitsma PH, Bertina RM. Homozygous protein S deficiency due to a one base pair deletion that leads to a stop codon in exon III of the protein S gene. Thromb Haemost. 1994;71:723-6.
18. Almeida JI, Coats R, Liem TK, Silver D. Reduced morbidity and mortality rates of the heparin-induced thrombocytopenia syndrome. J Vasc Surg. 1998; 27: 309-14.
19. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-7.
20. García-García C. Anticuerpos antifosfolípido y síndrome antifosfolípido: actitudes diagnósticas y terapéuticas. Actas Dermosifilogr. 2007;98:16-23.
21. Gantcheva M. Dermatologic aspects ofantiphospholipid syndrome. Int J Dermatol 1998;37:173-80.
22. Santamaría JR, Badziak D, Barros MF, Mandelli FL, Cavalin LC, Sato MS. An Bras Dermatol. 2005;80:225-39.
23. Diógenes MJ, Diógenes PC, de Morais Carneiro RM, Neto CC, Duarte FB, Holanda RR. Cutaneous manifestations associated with antiphospholipid antibodies. Int J Dermatol. 2004;43:632-7.
24. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y Camps MT, et al. Euro-Phospholipid Project Group. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002; 46:1019-27.
25. Francès C, Niang S, Laffitte E, Pelletier F, Costedoat N, Piette JC. Dermatologic manifestations of the antiphospholipid syndrome: two hundred consecutive cases. Arthritis Rheum. 2005;52:1785-93.
26. Kriseman YL, Nash JW, Hsu S. Criteria for the diagnosis of antiphospholipid syndrome in patients presenting with dermatologic symptoms. J Am Acad Dermatol. 2007;57:112-5.
27. Whitlatch NL, Ortel TL. Thrombophilias: when should we test and how does it help? Semin Respir Crit Care Med. 2008;29:25-39.
28. Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, et al. Women's Health Initiative Investigators. Estrogen plus progestin and risk of venous thrombosis. JAMA. 2004;292:1573-80.
29. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol. 1991;9:286-94.
30. Rajkumar SV. Thalidomide therapy and deep venous thrombosis in multiple myeloma. Mayo Clin Proc. 2005;80:1549-51.
31. Nadir Y, Mazor Y, Reuven B, Sarig G, Brenner B, Krivoy N. A fatal case of enoxaparin induced skin necrosis and thrombophilia. Eur J Haematol. 2006;77:166-8.
32. Bernstein CN, Blanchard JF, Houston DS, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost. 2001;85:430-4.
33. Bernstein CN, Wajda A, Blanchard JF. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. Clin Gastroenterol Hepatol. 2008;6:41-5.
34. Chan YC, Valenti D, Mansfield AO, Stansby G. Warfarin induced skin necrosis. Br J Surg. 2000;87:266-72.
35. Clivati Brandt HR, de Lorenzo Messina MC, Belda Júnior W, Costa Martins JE, Criado PR. Leg ulcers associated with factor V Leiden and prothrombin G20210A and methyltetrahydrofolate reductase mutations: successful treatment with warfarin. Int J Dermatol. 2007;46:1319-20.
36. Criado PR, Bernardelli IM, Rivitti EA, Sotto MN, Vilella MA, Valente NY, et al. Childhood-onset skin necrosis resulting from protein C deficiency. J Eur Acad Dermatol Venereol. 2007;21:537-9.
37. Lipsker D, Kara F. Images in clinical medicine. Retiform purpura. N Engl J Med. 2008;358:e1.
38. Jones A, Walling H. Retiform purpura in plaques: a morphological approach to diagnosis. Clin Exp Dermatol. 2007;32:596-602.
39. Kalajian AH, Turpen KB, Donovan KO, Malone JC, Callen JP. Phenylephrine-induced microvascular occlusion syndrome in a patient with a heterozygous factor V Leiden mutation. Arch Dermatol. 2007;143:1314-7.
40. Jorge AD, Fantini BC, Rivitti EA, Benabou JE, Vasconcellos C, Criado PR. Análise da freqüência de trombofilia em pacientes com atrofia branca de Milian. An Bras Dermatol. 2007;82:25-33.
41. Davis MD, "ysokinski "E. Ulcerations caused by livedoid vasculopathy associated with a prothrombotic state: Response to warfarin. J Am Acad Dermatol. 2008;58:512-5.
42. Anavekar NS, Kelly R. Heterozygous prothrombin gene mutation associated with livedoid vasculopathy. Australas J Dermatol. 2007;48:120-3.
43. Callen JP. Livedoid vasculopathy: what it is and how the patient should be evaluated and treated. Arch Dermatol. 2006;142:1481-2.
44. Hairston BR, Davis MD, Pittelkow MR, Ahmed I. Livedoid vasculopathy: further evidence for procoagulant pathogenesis. Arch Dermatol. 2006;142:1413-8.
45. Cocuroccia B, Tonanzi T, Menaguale G, Fazio M, Girolomoni G. Livedoid vasculopathy and skin ulcers in patients with inherited thrombophilia. Eur J Dermatol. 2002;12:360-3.
46. Biedermann T, Flaig MJ, Sander CA. Livedoid vasculopathy in a patient with factor V mutation (Leiden). J Cutan Pathol. 2000;27:410-2.
47. Gilaberte Coscojuela C, Lezaún A, Marigil MA. Degos disease associated with protein S deficiency. Br J Dermatol. 2005;153:666-7.
48. Gipstein RM, Coburn J", Adams DA, Lee DB, Parsa KP, Sellers A, et al. Calciphylaxis in man. A syndrome of tissue necrosis and vascular calcification in 11 patients with chronic renal failure. Arch Intern Med. 1976;136:1273-80.
49. Matsumura T, Matsumoto A, Ohno M, Suzuki S, Ohta M, Suzuki E, et al. A case of cholesterol embolism confirmed by skin biopsy and successfully treated with statins and steroids. Am J Med Sci. 2006;331:280-3.
50. Rachmilewitz EA, Sacks MI, Zlotnick A. Essential cryofibrinogenemia. Clinical, pathological and immunological studies. Isr J Med Sci. 1970;6:32-43.
51. Dodd HJ, Sarkany I, O'Shaughnessy D. Widespread cutaneous necrosis associated with the lupus anticoagulant. Clin Exp Dermatol. 1985;10:581-6.
52. Rossini J, Roverano S, Graf C, Paira S. Widespread cutaneous necrosis associated with antiphospholipid antibodies: report of four cases. J Clin Rheumatol. 2002;8:326-31.
53. Barrio VR, Sanfilippo AM, Malone JC, Callen JP. Nonhealing ulcer secondary to factor V Leiden mutation and cryofibrinogenemia. J Am Acad Dermatol. 2004;51:S194-6. Erratum in: J Am Acad Dermatol. 2004;51:1040.
54. Prasad HK, Govindarajan R. Heparin-induced skin necrosis associated with thrombocytopenia and acquired protein C and protein S deficiency. Am J Hematol. 2007;82:1116-7.
55. Silveira MT, Criado PR, Valente NYS, Vasconcellos C. Púrpura fulminante em paciente HIV positivo. An Bras Dermatol 2004;79(Suppl 2): S291-99.
56. Blume JE, Miller CC. Livedo reticularis with retiform purpura associated with gefitinib (Iressa ®). Int J Dermatol 2007;46:1307-8.
57. Kanazawa S, Yamaguchi K, Kinoshita Y, Muramatsu M, Komiyama Y, Nomura S. Gefitinib affects functions of platelets and blood vessels via changes in prostanoids balance. Clin Appl Thromb Hemost. 2005;11:429-34.
58. Bauer KA. The thrombophilias: well-defined risk factors with uncertain therapeutic implications. Ann Intern Med. 2001;135:367-73.
59. Perry SL, Ortel TL. Clinical and laboratory evaluation of thrombophilia. Clin Chest Med. 2003;24:153-70.
60. Moll S. Thrombophilias-practical implications and testing caveats. J Thromb Thrombolysis. 2006;21:7-15.
61. Lochhead P, Miedzybrodzka Z. The essential role of genetic counseling in inherited thrombophilia. Semin Hematol. 2007;44:126-9.
62. Simioni P, Tormene D, Prandoni P, Zerbinati P, Gavasso S, Cefalo P, et al. Incidence of venous thromboem- bolism in asymptomatic family members who are carriers of factor V Leiden: a prospective cohort study. Blood. 2002;99:1938-42.
63. Mavragani CP, Pikazis D, Aroni K, Paikos S, Voulgarelis M. Cutaneous ulcers: An unusual manifestation of inherited thrombophilia. Am J Hematol. 2004;76:139-42.
64. Renner R, Simon JC. Current therapeutic options of chronic leg ulcers. J Dtsch Dermatol Ges. 2008;6:389-401.
65. Bradbury AW, MacKenzie RK, Burns P, Fegan C. Thrombophilia and chronic venous ulceration. Eur J Vasc Endovasc Surg. 2002;24:97-104.
66. Brandt HR, de Lorenzo Messina MC, Hirayama JT, Belda W Jr, Benabou JE, Criado PR. Prevalence of thrombophilia associated with leg ulcers. Br J Dermatol. 2009;160(1):202-3.
67. Handel DW, Roenigk HH Jr, Shainoff J, Deodhar S. Necrotizing vasculitis. Etiologic aspects of immunology and coagulopathy. Arch Dermatol. 1975;111:847-52.
68. Bednarek N, Morville P, Delebarre G, Akhavi A, Sommer C. Necrotic skin lesions and cerebral infarction in the newborn: two case reports. J Child Neurol. 2007;22:354-7.
69. Agras PI, Ozdemir H, Baskin E, Ozbek N. Recurrent vasculopathic skin lesions associated with homozygous protein C deficiency. Pediatr Dermatol. 2007;24:57-60.
70. Uthman IW, Khamashta MA. Livedo racemosa: a striking dermatological sign for the antiphospholipid syndrome. J Rheumatol. 2006;33:2379-82.
71. Bauer KA. Management of thrombophilia. J Thromb Haemost. 2003;1:1429-34.